
Neumora Therapeutics Inc
NMRANASDAQ NMS - GLOBAL MARKETKey Statistics
Open
$1.89
Day High
$1.96
Day Low
$1.85
Prev. Close
$1.88
VolumeShares traded today.
884.87K
Avg. VolumeAverage daily volume.
—
Market CapTotal value of all shares = price × shares outstanding.
$342.78M
P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.
-1.39
Forward P/EP/E based on forecast next-year earnings.
—
P/B RatioPrice-to-Book: share price ÷ book value per share.
—
52W HighHighest price over the past 52 weeks.
$3.65
52W LowLowest price over the past 52 weeks.
$0.6900
50D MAAverage closing price over the last 50 trading days.
$2.11
200D MAAverage closing price over the last 200 trading days.
$2.20
Dividend YieldAnnual dividend ÷ share price, as a %.
—
BetaVolatility vs the market. >1 = more volatile than the S&P 500.
—
Performance
1W
+0.0%1M
-17.8%6M
-17.8%YTD
+11.4%1Y
+147.4%About
Navacaprant is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression. It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics. As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder. In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial. Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.
neumoratx.com/Company Facts
Similar stocks
Health CareSentiment
Latest News
Social Noise
Price Alerts
Loading…
Trade NMRA
Brokers available in your region (US)
Affiliate links — we may earn a commission. CFDs are risky.